Global uncertainties over the past two years, including US President Donald Trump’s tariff threats, price erosion in the generics market, and a Big Pharma shift towards biologics are forcing Indian drugmakers to seek new avenues of growth.
​Global uncertainties over the past two years, including US President Donald Trump’s tariff threats, price erosion in the generics market, and a Big Pharma shift towards biologics are forcing Indian drugmakers to seek new avenues of growth. by Soban News (international And National News)
